What Analysts Recommend for Accelerate Diagnostics and Peers

Tuscon-based Accelerate Diagnostics (AXDX) is a diagnostics company focused on developing solutions and tools to provide rapid diagnostic results. While results from traditional culture-based tests usually take two to three days, Accelerate’s technology platform is built to deliver substantially faster and more accurate testing of infectious pathogens.

Accelerate Diagnostics has been in the process of developing its rapid diagnostic platform called Accelerate Pheno since 2004. The platform is intended to rapidly diagnose infectious pathogens. The company aims to reduce the failure rate of initial antibiotic drug therapy by shortening the turnaround time in labs from two to three days to a few hours.

Of the four analysts covering Accelerate Diagnostics in January 2018, three analysts have given the stock a “buy” or a higher rating, while one analyst has given the stock a “hold” rating. The mean rating for the stock is 2.0 with a target price of $25.67.

Notably, Accelerate Diagnostics makes up about 0.03% of the iShares Russell 2000 ETF’s (IWM) total portfolio holding.

Of the total 19 analysts covering Becton Dickinson (BDX) in January 2018, 12 analysts have given the stock a “buy” or higher rating, while seven analysts have given it a “hold” rating. The mean rating for the stock is 2.0 with a target price of $234.69.

Of the 16 analysts covering Bruker (BRKR) in January 2018, three analysts have given the stock a “strong buy,” while 11 analysts give it a “hold” rating. The mean rating for the stock is 2.8 with a target price of $33.36.

Of the 17 analysts covering Thermo Fisher Scientific (TMO) in 2018, 16 analysts have given the stock a “buy” or a higher rating, while only one analyst has given it a “hold” rating. The mean rating for the stock is 1.5 with a target price of $219.63.

In the next part of the series, we’ll look at the potential market opportunity for Accelerate’s products.